ClinicalTrials.gg
CompletedNCT01987232Updated Aug 28, 2017Results posted

Phase 1b/2 Study of Carfilzomib, Carboplatin, and Etoposide in Patients With Previously Untreated Extensive Stage Small-cell Lung Cancer

A Phase 1/2 interventional study of Carfilzomib and Carboplatin in Extensive-Stage Small-Cell Lung Cancer, sponsored by Amgen. Completed at 17 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-08-28.

Sponsored by Amgen · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
32
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 36 studies testing carboplatin in Small Cell Lung Carcinoma — 6 open to participants now, 9 under way, 1 of them phase 3. Carboplatin · Small Cell Lung Carcinoma.

Enrollment
25th of 36
32 · median 48
Started
2013
with 1 other
Phase 1/2
4 of 36
1 open now
Registered
14th of 36
by date
Lead sponsor
1 of 36
Amgen

Among the 36 studies testing carboplatin in Small Cell Lung Carcinoma, this one is the 25th largest by enrollment, is one of 2 that started in 2013, is one of 4 in phase 1/2, and was the 14th registered.

Small Cell Lung Carcinoma

1,301 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.

Browse Small Cell Lung Carcinoma studies →

Open to participants now

6 of the 36 studies testing carboplatin in Small Cell Lung Carcinoma are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About carboplatin

Carboplatin: first FDA approval 1989 (PARAPLATIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 265 Small Cell Lung Carcinoma studies recruiting now, 175 (66%) set no upper age limit and 66 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing carboplatin in Small Cell Lung Carcinoma, or all of them as a file.
02

Study summary

The purpose of this study is to determine the maximum tolerated dose and assess the safety, tolerability and activity of carfilzomib given in combination with carboplatin and etoposide as initial therapy for patients with extensive-stage small-cell lung cancer (ES SCLC).

03

Conditions studied

  • Extensive-Stage Small-Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. or cytologically confirmed diagnosis of extensive-stage small-cell lung cancer (ES-SCLC) with per (RECIST) Version 1.1; ES-SCLC is defined as: small-cell lung cancer (SCLC) that has spread beyond one hemithorax and regional lymph nodes on the same side (e.g., supraclavicular) to the contralateral hemithorax, lymph nodes, or more distant locations in the body
  2. Subjects with asymptomatic or other central nervous system (CNS) disease at screening/diagnosis are eligible
  3. Males and females ≥ 18 years of age
  4. (ECOG) performance status 0-1

Key Exclusion Criteria:

  1. Previous systemic therapy to treat small-cell lung cancer (SCLC). Subjects with recurrent or progressive limited-stage SCLC after previous systemic treatment are not eligible for study participation.
  2. Whole brain or focal radiation therapy within 14 days prior to Cycle 1 Day 1 (C1D1) for Phase 1b or prior to randomization for Phase 2
  3. Congestive heart failure ( [NYHA] class III to IV), symptomatic ischemia, conduction abnormalities uncontrolled by conventional intervention, or myocardial infarction within 6 months prior to prior to C1D1 for Phase 1b or prior to randomization for Phase 2
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Carfilzomib Combination

    Participants received carfilzomib on days 2, 3, 9, and 10 of each 21-day cycle as per the dose escalation schema, carboplatin at a target area under the curve (AUC) of 5 on day 1 of each cycle, and etoposide 100 mg/m² on days 1, 2, 3 of each 21-day cycle for up to 6 cycles. Participants with stable disease or better continued to receive carfilzomib alone until progressive disease (PD), unacceptable toxicity, withdrawal of consent, study closure, or death, whichever occurred earliest.

    Drug: Carfilzomib · Drug: Carboplatin · Drug: Etoposide

Interventions

  • Administered by intravenous infusion.

    Also known as: PR-171, PR171, Kyprolis®

  • Administered by intravenous infusion.

  • Administered by intravenous infusion.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Dose-limiting Toxicities

    The maximum tolerated dose (MTD) was defined as the highest dose level at which \< 33% of participants experienced a dose-limiting toxicity (DLT) during the first 21-day cycle. Dose-limiting toxicities were evaluated according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 4.03. A DLT was defined as: * A grade 3 or greater non-hematologic toxicity that was assessed as related to carfilzomib by the investigator except in the case of neuropathy. A grade 2 or higher neuropathy with pain was considered a DLT. * Grade 4 neutropenia: absolute neutrophil count (ANC) \< 500 mm³, lasting ≥ 7 days despite granulocyte colony stimulating factor support, or any febrile (temperature \> 38.3°C) neutropenia (ANC \< 1000 mm³). * Thrombocytopenia of any grade associated with clinically significant bleeding or platelet/blood transfusion * Grade 4 fatigue lasting ≥ 7 days * Grade 3 nausea, vomiting or diarrhea lasting ≥ 7 days.

    Time frame: First 21-day Cycle

Secondary outcomes

  1. Number of Participants With Adverse Events (AEs)

    The severity of each adverse event was assessed using the NCI-CTCAE Version 4.03 according to the following: Grade 1 - Mild: Asymptomatic or mild symptoms; intervention not indicated Grade 2 - Moderate: Minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living (ADL) Grade 3 - Severe: Medically significant but not life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL Grade 4 - Life-threatening Grade 5 - Fatal. A serious AE is an AE that met one or more of the following criteria: * Death * Life-threatening * Required inpatient hospitalization or prolongation of an existing hospitalization * Resulted in persistent or significant disability/incapacity * A congenital anomaly/birth defect * Important medical events that required medical or surgical intervention to prevent one of the outcomes above.

    Time frame: From first day of any study treatment (i.e., carfilzomib, carboplatin, or etoposide) up to 30 days after the last day of study treatment. The median overall duration of treatment was 16 weeks.

  2. Overall Survival (OS) - Phase 2

    Overall Survival (OS) is defined as the time from randomization to the date of death. Overall survival was a specified secondary endpoint for the phase 2 portion of the study; since phase 2was not conducted, OS was not analyzed.

    Time frame: 30 months

  3. Maximum Plasma Concentration - Phase 2

    Pharmacokinetic (PK) analyses were specified as secondary endpoints for the phase 2 portion of the study; since phase 2 was not conducted, PK analyses were not performed.

    Time frame: Cycle 1 Day 2

  4. Time of Maximum Plasma Concentration - Phase 2

    Pharmacokinetic (PK) analyses were specified as secondary endpoints for the phase 2 portion of the study; since phase 2 was not conducted, PK analyses were not performed.

    Time frame: Cycle 1 Day 2

  5. Area Under Plasma Concentration-Time Curve - Phase 2

    Pharmacokinetic (PK) analyses were specified as secondary endpoints for the phase 2 portion of the study; since phase 2 was not conducted, PK analyses were not performed.

    Time frame: Cycle 1 Day 2

Other outcomes

  1. Progression-free Survival

    Progression-free survival (PFS) was specified as a primary endpoint for the phase 2 portion of the study. Since phase 2 did not proceed PFS was analyzed in phase 1b participants on an exploratory basis. PFS was defined as the time from the start of treatment to documented disease progression or death due to any cause, whichever occurred first. Disease progression was determined by the investigator according to the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, defined as at least a 20% increase in the size of target lesions (absolute increase ≥ 5 mm), unequivocal progression of existing non-target lesions, or any new lesions. Median PFS was calculated using Kaplan-Meier methods. Participants with no baseline disease assessments, who started a new anticancer therapy before documentation of PD or death, with death or PD immediately after more than 1 consecutively missed disease assessment visit or alive without documentation of PD before the data cutoff date were censored.

    Time frame: From first dose of study drug until the end of treatment; median duration of treatment was 16 weeks.

  2. Overall Response Rate

    The overall response rate (ORR) was defined as the percentage of participants for whom the best overall confirmed response was either complete response (CR) or partial response (PR) assessed by the investigator according to RECIST v1.1 criteria. CR: Disappearance of all target and non-target lesions, no new lesions and normalization of tumor marker levels. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters, or, the disappearance of all target lesions and persistence of one or more non-target lesion(s) and/or maintenance of tumor marker levels above normal limits.

    Time frame: From first dose of study drug until the end of treatment; median duration of treatment was 16 weeks.

  3. Duration of Response

    Duration of response (DOR) was calculated for participants who achieved a confirmed CR or PR. defined as the time from first evidence of confirmed PR/CR to disease progression or death due to any cause. Median DOR was calculated using Kaplan-Meier methods. Participants with no baseline disease assessments, who started a new anticancer therapy before documentation of PD or death, with death or PD immediately after more than 1 consecutively missed disease assessment visit or alive without documentation of PD before the data cutoff date were censored. DOR was originally specified as a secondary endpoint for the phase 2 portion of the study. Since phase 2 did not proceed, DOR was analyzed in phase 1b participants on an exploratory basis.

    Time frame: From first dose of study drug until the end of treatment; median duration of treatment was 16 weeks.

07

Results

Posted Aug 28, 2017

Participant flow

This study was conducted at 17 centers in the United States, Russia, and Canada.

Participant flow — Overall Study
MilestoneCarfilzomib 20/20 mg/m²Carfilzomib 20/27 mg/m²Carfilzomib 20/36 mg/m²Carfilzomib 20/45 mg/m²Carfilzomib 20/56 mg/m²
Started533156
Completed533146
Not completed00010
Withdrew: Ongoing in study00010

Outcome measures

PrimaryNumber of Participants With Dose-limiting Toxicities

The maximum tolerated dose (MTD) was defined as the highest dose level at which \< 33% of participants experienced a dose-limiting toxicity (DLT) during the first 21-day cycle. Dose-limiting toxicities were evaluated according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 4.03. A DLT was defined as: * A grade 3 or greater non-hematologic toxicity that was assessed as related to carfilzomib by the investigator except in the case of neuropathy. A grade 2 or higher neuropathy with pain was considered a DLT. * Grade 4 neutropenia: absolute neutrophil count (ANC) \< 500 mm³, lasting ≥ 7 days despite granulocyte colony stimulating factor support, or any febrile (temperature \> 38.3°C) neutropenia (ANC \< 1000 mm³). * Thrombocytopenia of any grade associated with clinically significant bleeding or platelet/blood transfusion * Grade 4 fatigue lasting ≥ 7 days * Grade 3 nausea, vomiting or diarrhea lasting ≥ 7 days.

Time frame:
First 21-day Cycle
Reported as:
Count of participants · Participants
Number of Participants With Dose-limiting Toxicities
ParticipantsCarfilzomib 20/20 mg/m²Carfilzomib 20/27 mg/m²Carfilzomib 20/36 mg/m²Carfilzomib 20/45 mg/m²Carfilzomib 20/56 mg/m²
Number of Participants With Dose-limiting Toxicities00001
SecondaryNumber of Participants With Adverse Events (AEs)

The severity of each adverse event was assessed using the NCI-CTCAE Version 4.03 according to the following: Grade 1 - Mild: Asymptomatic or mild symptoms; intervention not indicated Grade 2 - Moderate: Minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living (ADL) Grade 3 - Severe: Medically significant but not life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL Grade 4 - Life-threatening Grade 5 - Fatal. A serious AE is an AE that met one or more of the following criteria: * Death * Life-threatening * Required inpatient hospitalization or prolongation of an existing hospitalization * Resulted in persistent or significant disability/incapacity * A congenital anomaly/birth defect * Important medical events that required medical or surgical intervention to prevent one of the outcomes above.

Time frame:
From first day of any study treatment (i.e., carfilzomib, carboplatin, or etoposide) up to 30 days after the last day of study treatment. The median overall duration of treatment was 16 weeks.
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs)
ParticipantsCarfilzomib 20/20 mg/m²Carfilzomib 20/27 mg/m²Carfilzomib 20/36 mg/m²Carfilzomib 20/45 mg/m²Carfilzomib 20/56 mg/m²
Any adverse event533155
Adverse events ≥ grade 3332134
Serious adverse events11172
AEs leading to disocontinuation of study drug10031
Fatal adverse events00001
SecondaryOverall Survival (OS) - Phase 2

Overall Survival (OS) is defined as the time from randomization to the date of death. Overall survival was a specified secondary endpoint for the phase 2 portion of the study; since phase 2was not conducted, OS was not analyzed.

Time frame:
30 months

No measurements were reported for this outcome.

SecondaryMaximum Plasma Concentration - Phase 2

Pharmacokinetic (PK) analyses were specified as secondary endpoints for the phase 2 portion of the study; since phase 2 was not conducted, PK analyses were not performed.

Time frame:
Cycle 1 Day 2

No measurements were reported for this outcome.

SecondaryTime of Maximum Plasma Concentration - Phase 2

Pharmacokinetic (PK) analyses were specified as secondary endpoints for the phase 2 portion of the study; since phase 2 was not conducted, PK analyses were not performed.

Time frame:
Cycle 1 Day 2

No measurements were reported for this outcome.

SecondaryArea Under Plasma Concentration-Time Curve - Phase 2

Pharmacokinetic (PK) analyses were specified as secondary endpoints for the phase 2 portion of the study; since phase 2 was not conducted, PK analyses were not performed.

Time frame:
Cycle 1 Day 2

No measurements were reported for this outcome.

Other pre-specifiedProgression-free Survival

Progression-free survival (PFS) was specified as a primary endpoint for the phase 2 portion of the study. Since phase 2 did not proceed PFS was analyzed in phase 1b participants on an exploratory basis. PFS was defined as the time from the start of treatment to documented disease progression or death due to any cause, whichever occurred first. Disease progression was determined by the investigator according to the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, defined as at least a 20% increase in the size of target lesions (absolute increase ≥ 5 mm), unequivocal progression of existing non-target lesions, or any new lesions. Median PFS was calculated using Kaplan-Meier methods. Participants with no baseline disease assessments, who started a new anticancer therapy before documentation of PD or death, with death or PD immediately after more than 1 consecutively missed disease assessment visit or alive without documentation of PD before the data cutoff date were censored.

Time frame:
From first dose of study drug until the end of treatment; median duration of treatment was 16 weeks.
Reported as:
Median · months
Progression-free Survival
monthsCarfilzomib 20/20 mg/m²Carfilzomib 20/27 mg/m²Carfilzomib 20/36 mg/m²Carfilzomib 20/45 mg/m²Carfilzomib 20/56 mg/m²All Participants
Progression-free Survival4.0 (2.8 to 6.7)6.4 (6.2 to 6.8)7.0 (4.0 to 7.0)2.9 (2.5 to 5.4)3.8 (1.1 to 6.3)4.4 (2.8 to 5.6)
Other pre-specifiedOverall Response Rate

The overall response rate (ORR) was defined as the percentage of participants for whom the best overall confirmed response was either complete response (CR) or partial response (PR) assessed by the investigator according to RECIST v1.1 criteria. CR: Disappearance of all target and non-target lesions, no new lesions and normalization of tumor marker levels. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters, or, the disappearance of all target lesions and persistence of one or more non-target lesion(s) and/or maintenance of tumor marker levels above normal limits.

Time frame:
From first dose of study drug until the end of treatment; median duration of treatment was 16 weeks.
Reported as:
Number · percentage of participants
Overall Response Rate
percentage of participantsCarfilzomib 20/20 mg/m²Carfilzomib 20/27 mg/m²Carfilzomib 20/36 mg/m²Carfilzomib 20/45 mg/m²Carfilzomib 20/56 mg/m²All Participants
Overall Response Rate60.0 (14.7 to 94.7)100.0 (29.2 to 100.0)66.7 (9.4 to 99.2)33.3 (11.8 to 61.6)33.3 (4.3 to 77.7)46.9 (29.1 to 65.3)
Other pre-specifiedDuration of Response

Duration of response (DOR) was calculated for participants who achieved a confirmed CR or PR. defined as the time from first evidence of confirmed PR/CR to disease progression or death due to any cause. Median DOR was calculated using Kaplan-Meier methods. Participants with no baseline disease assessments, who started a new anticancer therapy before documentation of PD or death, with death or PD immediately after more than 1 consecutively missed disease assessment visit or alive without documentation of PD before the data cutoff date were censored. DOR was originally specified as a secondary endpoint for the phase 2 portion of the study. Since phase 2 did not proceed, DOR was analyzed in phase 1b participants on an exploratory basis.

Time frame:
From first dose of study drug until the end of treatment; median duration of treatment was 16 weeks.
Reported as:
Median · months
Duration of Response
monthsCarfilzomib 20/20 mg/m²Carfilzomib 20/27 mg/m²Carfilzomib 20/36 mg/m²Carfilzomib 20/45 mg/m²Carfilzomib 20/56 mg/m²All Participants
Duration of Response4.9 (2.8 to 5.4)5.0 (4.7 to 5.6)NA (2.8 to NA)4.3 (1.6 to NA)4.5 (4.2 to 4.8)4.8 (2.8 to 5.4)

Adverse events

Collected over From first day of any study treatment (i.e., carfilzomib, carboplatin, or etoposide), and within 30 days of the last day of study treatment. The median overall duration of treatment was 16 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Carfilzomib 20/20 mg/m²—1/5 (20%)5/5 (100%)
Carfilzomib 20/27 mg/m²—1/3 (33.3%)3/3 (100%)
Carfilzomib 20/36 mg/m²—1/3 (33.3%)3/3 (100%)
Carfilzomib 20/45 mg/m²—7/15 (46.7%)15/15 (100%)
Carfilzomib 20/56 mg/m²—2/6 (33.3%)5/6 (83.3%)
Most frequent serious events
Showing 10 of 16
Most frequent serious events
EventCarfilzomib 20/20 mg/m²Carfilzomib 20/27 mg/m²Carfilzomib 20/36 mg/m²Carfilzomib 20/45 mg/m²Carfilzomib 20/56 mg/m²
Febrile neutropeniaBlood and lymphatic system disorders0/50/31/32/150/6
Clostridium difficile colitisInfections and infestations0/50/31/30/150/6
PneumoniaInfections and infestations0/51/30/31/151/6
Fluid overloadMetabolism and nutrition disorders0/51/30/30/150/6
Cerebrovascular accidentNervous system disorders1/50/30/30/150/6
AnaemiaBlood and lymphatic system disorders0/50/30/30/151/6
Atrial fibrillationCardiac disorders0/50/30/30/151/6
Pulmonary haemorrhageRespiratory, thoracic and mediastinal disorders0/50/30/30/151/6
Injection site abscessInfections and infestations0/50/30/31/150/6
HypoalbuminaemiaMetabolism and nutrition disorders0/50/30/31/150/6
Most frequent other events
Showing 10 of 143
Most frequent other events
EventCarfilzomib 20/20 mg/m²Carfilzomib 20/27 mg/m²Carfilzomib 20/36 mg/m²Carfilzomib 20/45 mg/m²Carfilzomib 20/56 mg/m²
AnaemiaBlood and lymphatic system disorders2/53/32/38/153/6
NauseaGastrointestinal disorders3/53/33/35/151/6
NeutropeniaBlood and lymphatic system disorders1/52/30/310/153/6
ThrombocytopeniaBlood and lymphatic system disorders0/52/31/37/154/6
DiarrhoeaGastrointestinal disorders1/52/31/35/150/6
Neutrophil count decreasedInvestigations1/52/30/30/151/6
Platelet count decreasedInvestigations0/52/30/32/152/6
Decreased appetiteMetabolism and nutrition disorders2/50/32/32/151/6
HypomagnesaemiaMetabolism and nutrition disorders0/52/30/30/151/6
HyponatraemiaMetabolism and nutrition disorders0/52/31/30/151/6

Baseline characteristics

Age, Continuous
Age, Continuous(years)Carfilzomib 20/20 mg/m²Carfilzomib 20/27 mg/m²Carfilzomib 20/36 mg/m²Carfilzomib 20/45 mg/m²Carfilzomib 20/56 mg/m²Total
Mean69.2 ± 13.862.3 ± 8.559.0 ± 7.556.9 ± 9.458.8 ± 7.959.9 ± 10.1
Age, Customized
Age, Customized(Participants)Carfilzomib 20/20 mg/m²Carfilzomib 20/27 mg/m²Carfilzomib 20/36 mg/m²Carfilzomib 20/45 mg/m²Carfilzomib 20/56 mg/m²Total
< 65 years22214525
≥ 65 years311117
Sex: Female, Male
Sex: Female, Male(Participants)Carfilzomib 20/20 mg/m²Carfilzomib 20/27 mg/m²Carfilzomib 20/36 mg/m²Carfilzomib 20/45 mg/m²Carfilzomib 20/56 mg/m²Total
Female3215112
Male21210520
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Carfilzomib 20/20 mg/m²Carfilzomib 20/27 mg/m²Carfilzomib 20/36 mg/m²Carfilzomib 20/45 mg/m²Carfilzomib 20/56 mg/m²Total
Hispanic or Latino000101
Not Hispanic or Latino53314530
Unknown or Not Reported000011
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Carfilzomib 20/20 mg/m²Carfilzomib 20/27 mg/m²Carfilzomib 20/36 mg/m²Carfilzomib 20/45 mg/m²Carfilzomib 20/56 mg/m²Total
White53314631
Other000101
Eastern Cooperative Oncology Group (ECOG) Performance Status
Eastern Cooperative Oncology Group (ECOG) Performance Status(Participants)Carfilzomib 20/20 mg/m²Carfilzomib 20/27 mg/m²Carfilzomib 20/36 mg/m²Carfilzomib 20/45 mg/m²Carfilzomib 20/56 mg/m²Total
0 (Fully active)4013210
1 (Restrictive but ambulatory)13212422
08

Study locations

17 sites
  • Yale University, Yale Cancer Center
    New Haven, Connecticut, United States
  • UF Health Davis Cancer Pavilion and Shands Med Plaza
    Gainesville, Florida, United States
  • Goshen Center for Cancer Care
    Goshen, Indiana, United States
  • Horizon Oncology Research, Inc.
    Lafayette, Indiana, United States
  • Indiana University Health Ball Memorial Hospital
    Muncie, Indiana, United States
  • Baptist Health Lexington Clinical Research Center
    Lexington, Kentucky, United States
  • Frederick Memorial Hospital
    Frederick, Maryland, United States
  • John Theurer Cancer Center at Hackensack UMC
    Hackensack, New Jersey, United States
  • Levine Cancer Institute
    Charlotte, North Carolina, United States
  • Wake Forest Baptist Health
    Winston-Salem, North Carolina, United States
  • The University of Texas MD Anderson Cancer Center
    Houston, Texas, United States
  • Juravinski Cancer Centre
    Hamilton, Ontario, Canada
  • Regional Budgetary Healthcare Institution "Kursk Regional Clinical Oncology Dispensary"
    Kislino, Kursk, Russian Federation
  • State budgetary healthcare institution of Arkhangelsk Region "Arkhangelsk Clinical Oncological Dispensary"
    Arkhangelsk, Russian Federation
  • Federal State Budgetary Scientific Institution "N.N. Blokhin Russian Cancer Research Center"
    Moscow, Russian Federation
  • State Budgetary Educational Inslitution of Higher Professional Education "First St. Petersburg I.P.Pavlov State Medical University"
    St. Petersburg, Russian Federation
  • State Budgetary Healthcare Institution of Yaroslavl Region "Regional Clinical Oncological Hospital"
    Yaroslavl, Russian Federation
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2013, a primary completion of Aug 2016 and a completion of May 2017. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2017, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 6, 2013
First posted
Nov 19, 2013
Start
Nov 5, 2013
Primary completionActual
Aug 2016
CompletionActual
May 4, 2017
Results first posted
Aug 28, 2017
Last update
Aug 28, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 28, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01987232
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Nov 19, 2013
Start date
Nov 5, 2013
Primary completion
Aug 2016
Completion
May 4, 2017
Results posted
Aug 28, 2017
Last update
Aug 28, 2017

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Carfilzomib · Carboplatin · Etoposide

Start the discussion